NovoCure Financials - Benzinga

NovoCure Ltd

NVCRNASDAQ

Trade with Public

Trade with Public

$16.25

-0.42-2.52%

In chiusura: Sep 22, 5:00 PM EST

$16.05

-0.62-3.72%

Pre-mercato: 8:04 AM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

NovoCure Financials

NovoCure (NVCR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding

NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.

Akanksha Bakshi

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report

Benzinga Insights

PRO
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est

NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.

Benzinga Newsdesk

PRO
NovoCure Q2 EPS $(0.13) Beats $(0.33) Estimate, Sales $183.584M Beat $172.437M Estimate

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.33) by 60.61 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the

Benzinga Newsdesk

PRO
NovoCure Raises FY2026 Sales Guidance from $675.000M-$705.000M to $690.000M-$710.000M vs $692.115M Est

NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $675.000 million-$705.000 million to $690.000 million-$710.000 million vs $692.115 million estimate.

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved